J Clin Oncol 38 (17): 1887-1896, 2020.[PUBMED Abstract] Modi S, Jacot W, Yamashita T, et al.: Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med 387 (1): 9-20, 2022.[PUBMED Abstract] Bardia A, Hu X, Dent R, et al.: Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
N Engl J Med 391 (22): 2110-2122, 2024.[PUBMED Abstract] Cortes J, Cescon DW, Rugo HS, et al.: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.